YU86501A - Derivati etansulfonil-piperidina - Google Patents

Derivati etansulfonil-piperidina

Info

Publication number
YU86501A
YU86501A YU86501A YUP86501A YU86501A YU 86501 A YU86501 A YU 86501A YU 86501 A YU86501 A YU 86501A YU P86501 A YUP86501 A YU P86501A YU 86501 A YU86501 A YU 86501A
Authority
YU
Yugoslavia
Prior art keywords
disease
neurodegeneration
compounds
chronic
denotes
Prior art date
Application number
YU86501A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buttelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU86501A publication Critical patent/YU86501A/sh
Publication of RS50033B publication Critical patent/RS50033B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja opšte formule (I) u kojoj R1 označava vodonik ili hidroksi, R2 označava vodonik ili metil i X označava -O- ili -CH2-, i njihove farmaceutski prihvatljive kiselinske adicione soli. Pokazano je da ova jedinjenja imaju dobar afinitet prema NMDA receptoru i otuda su prikladna u lečenju bolesti, pri čemu ove terapeutske indikacije uključuju akutne oblike neurodegeneracije koji su prouzrokovani, npr., moždanim udarom ili moždanom traumom, hronične oblike neurodegeneracije kao što su Alchajmerova bolest, Parkinsonova bolest, Hantingtonova bolest ili ALS (amiotrofična lateralna skleroza), neurodegeneracije koja je u vezi sa bakterijskim ili virusnim infekcijama, i bolesti kao što su shizofrenija, brižnost (anksioznost), depresija i hronični/akutni bol.
YUP-865/01A 1999-06-08 2000-05-31 Derivati etansulfonil-piperidina RS50033B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (2)

Publication Number Publication Date
YU86501A true YU86501A (sh) 2004-09-03
RS50033B RS50033B (sr) 2008-11-28

Family

ID=8238316

Country Status (38)

Country Link
US (1) US6310213B1 (sh)
EP (1) EP1189886B1 (sh)
JP (1) JP3645856B2 (sh)
KR (1) KR100571162B1 (sh)
CN (1) CN1142141C (sh)
AR (1) AR024282A1 (sh)
AT (1) ATE315025T1 (sh)
AU (1) AU770787B2 (sh)
BR (1) BR0011419A (sh)
CA (1) CA2376091C (sh)
CO (1) CO5160328A1 (sh)
CZ (1) CZ299483B6 (sh)
DE (1) DE60025348T2 (sh)
DK (1) DK1189886T3 (sh)
EG (1) EG26101A (sh)
ES (1) ES2254183T3 (sh)
GC (1) GC0000256A (sh)
GT (1) GT200000089A (sh)
HK (1) HK1046412B (sh)
HR (1) HRP20010885B1 (sh)
HU (1) HU228591B1 (sh)
IL (2) IL146750A0 (sh)
JO (1) JO2260B1 (sh)
MA (1) MA26797A1 (sh)
MX (1) MXPA01012585A (sh)
MY (1) MY128818A (sh)
NO (1) NO320613B1 (sh)
PA (1) PA8496601A1 (sh)
PE (1) PE20010218A1 (sh)
PL (1) PL196053B1 (sh)
RS (1) RS50033B (sh)
RU (1) RU2242464C2 (sh)
SI (1) SI1189886T1 (sh)
TN (1) TNSN00125A1 (sh)
TR (1) TR200103532T2 (sh)
TW (1) TWI254043B (sh)
WO (1) WO2000075109A1 (sh)
ZA (1) ZA200109706B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225330T3 (es) * 2000-03-22 2005-03-16 Hoffmann La Roche Compuesto de piperidina y piperacina para empleo en el tratamiento de alzheimer.
ATE274494T1 (de) * 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
JP4228048B2 (ja) * 2000-10-09 2009-02-25 ピーオーダブリューエムアールアイ リミテッド 神経変性障害の検出方法
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2268715C1 (ru) * 2004-06-22 2006-01-27 ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) Нейропротекторное средство
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
EP2734041A4 (en) * 2011-07-18 2015-03-25 Adolor Corp METHOD FOR THE PRODUCTION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATE PRODUCTS THEREOF
WO2024217539A1 (zh) * 2023-04-20 2024-10-24 纽欧申医药(上海)有限公司 含氮杂环类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594729A1 (en) * 1991-07-17 1994-05-04 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CZ20014349A3 (cs) 2002-05-15
WO2000075109A1 (en) 2000-12-14
JO2260B1 (en) 2004-10-07
GC0000256A (en) 2006-11-01
CN1354745A (zh) 2002-06-19
IL146750A0 (en) 2002-07-25
AR024282A1 (es) 2002-09-25
US6310213B1 (en) 2001-10-30
GT200000089A (es) 2001-11-29
HRP20010885B1 (en) 2010-07-31
TR200103532T2 (tr) 2002-05-21
PL352723A1 (en) 2003-09-08
EP1189886B1 (en) 2006-01-04
DE60025348D1 (de) 2006-03-30
ATE315025T1 (de) 2006-02-15
CZ299483B6 (cs) 2008-08-13
EP1189886A1 (en) 2002-03-27
NO320613B1 (no) 2005-12-27
KR20020008850A (ko) 2002-01-31
HRP20010885A2 (en) 2004-02-29
DE60025348T2 (de) 2006-08-24
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
HUP0201916A3 (en) 2003-05-28
AU770787B2 (en) 2004-03-04
IL146750A (en) 2006-12-10
HU228591B1 (hu) 2013-04-29
CA2376091A1 (en) 2000-12-14
MA26797A1 (fr) 2004-12-20
KR100571162B1 (ko) 2006-04-17
CN1142141C (zh) 2004-03-17
EG26101A (en) 2013-02-17
RU2242464C2 (ru) 2004-12-20
ES2254183T3 (es) 2006-06-16
MY128818A (en) 2007-02-28
PE20010218A1 (es) 2001-02-28
SI1189886T1 (sl) 2006-04-30
ZA200109706B (en) 2003-02-26
JP2003501415A (ja) 2003-01-14
PL196053B1 (pl) 2007-11-30
HUP0201916A2 (en) 2002-10-28
HK1046412B (zh) 2004-07-09
PA8496601A1 (es) 2001-12-14
AU5218100A (en) 2000-12-28
CO5160328A1 (es) 2002-05-30
CA2376091C (en) 2006-03-14
DK1189886T3 (da) 2006-05-15
NO20015920D0 (no) 2001-12-04
HK1046412A1 (en) 2003-01-10
BR0011419A (pt) 2002-02-26
MXPA01012585A (es) 2002-04-10
NO20015920L (no) 2001-12-04
JP3645856B2 (ja) 2005-05-11
TWI254043B (en) 2006-05-01

Similar Documents

Publication Publication Date Title
CA2407345A1 (en) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
YU86501A (sh) Derivati etansulfonil-piperidina
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
DK1267866T3 (da) Behandling af respirationssygdomme
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0212185A (pt) Compostos e métodos para a preparação de compostos
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
BRPI0113146B8 (pt) "derivados de prolina e composição farmacêutica que os compreende".
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0416216A (pt) composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
BR0311177A (pt) (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda
YU33401A (sh) 13-točlani azalidi i njihova primena kao antibiotičkih sredstava
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
BR9801157A (pt) Derivados de adamantano substituìdos por flúor.
CA2126118A1 (en) 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative
YU86701A (sh) Jedinjenja i formulacije za inhibiciju agregacije proteina i snimanje amiloidnih naslaga
AR037249A1 (es) Compuestos derivados de piridina, un procedimiento para prepararlos y medicamentos que los contienen
BR0213907A (pt) Derivados de heteroarila como ligandos superiores para receptor de nociceptina orl-1
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
CA2431761A1 (en) Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
ECSP003519A (es) Derivados de etanosulfonilo-piperidina
TH60812A (th) อนุพันธ์อีเธนซัลโฟนิล-พิเพอริดีน
YU48296A (sh) Polimorfni oblici proleka 6-n(l-ala-l-ala)-trovafloksacina, postupci za dobijanje i njihove farmaceutske kompozicije
FI922518A7 (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi